Wall Street analysts expect that Natus Medical Incorporated (NASDAQ:NTUS) will announce earnings per share (EPS) of $0.38 for the current quarter, according to Zacks. Two analysts have issued estimates for Natus Medical’s earnings. The highest EPS estimate is $0.38 and the lowest is $0.37. Natus Medical posted earnings of $0.40 per share during the same quarter last year, which would suggest a negative year over year growth rate of 5%. The company is expected to announce its next quarterly earnings results on Wednesday, October 23rd.
On average, analysts expect that Natus Medical will report full-year earnings of $1.28 per share for the current year, with EPS estimates ranging from $1.27 to $1.28. For the next financial year, analysts expect that the company will post earnings of $1.72 per share, with EPS estimates ranging from $1.68 to $1.76. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Natus Medical.
Natus Medical (NASDAQ:NTUS) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.34 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.04. Natus Medical had a negative net margin of 7.38% and a positive return on equity of 10.73%. The firm had revenue of $125.54 million during the quarter, compared to the consensus estimate of $122.85 million.
NASDAQ:NTUS traded down $1.12 during trading hours on Friday, hitting $30.27. The stock had a trading volume of 6,375 shares, compared to its average volume of 259,077. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.93 and a quick ratio of 1.36. Natus Medical has a one year low of $22.25 and a one year high of $37.50. The company has a market cap of $1.09 billion, a price-to-earnings ratio of 21.31 and a beta of 0.63.
About Natus Medical
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.